BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services Contract Manufacturing

WuXi Biologics Secures U.S. Patent for WuXiBody™ Antibody Tech

WuXiBodyTM has been widely adopted globally since its launch in 2018. It can effectively break through the CMC barriers for the development of many bi...

January 17, 2024 | News

WuXi Biologics and BioNTech Partner on Monoclonal Antibody Research Agreement

Under the terms of the agreement, WuXi Biologics leverages its proprietary antibody discovery technology platforms (R in CRDMO) to discover two undisclosed...

January 11, 2024 | News

WuXi AppTec Triples Peptide Capacity, Launches Taixing API Site

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech an...

January 09, 2024 | News

AGC Biologics to Open New Manufacturing Site in Yokohama, Japan

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced plans to construct...

January 05, 2024 | News

WuXi XDC Partners with IntoCell to Boost ADC Discovery and Development

Under the agreement, IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and novel...

January 03, 2024 | News

AstraZeneca Acquires Gracell, Expanding Cell Therapy Goals in Oncology and Autoimmune Diseases.

AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceuti...

December 28, 2023 | News

AGC announces strategic expansion of its Biopharmaceutical CDMO capability in Yokohama, Japan, signaling a new era of innovation and growth

This expansion has been selected by the Japanese Ministry of Economy, Trade and Industry (METI) as part of its "Developing biopharmaceutical manufacturin...

December 26, 2023 | News

Genevoyager (Wuhan) Launches State-of-the-Art CDMO Facility to Propel Gene Therapy Advancements

The newly inaugurated cGMP facility is equipped with its proprietary One-Bac 4.0 System with Sf-RVF® cell line and adheres to the NMPA, FDA and EM...

December 21, 2023 | News

WuXi Vaccines Passes First GMP Audit by a Global Vaccine Leader

The three-day comprehensive audit covered the CDMO site's drug substance (DS) facility, drug product (DP) facility, QC laboratories, warehouse, and utiliti...

December 07, 2023 | News

GMP cell CDMO I Peace, Inc. obtains accreditation as ISO 17025: 2017 compliant

Leading GMP cell CDMO I Peace, Inc. , specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that its&...

December 07, 2023 | News

Merck Expands Newest Biologics Testing Center in Shanghai

Further develops its biosafety testing laboratories to meet local demand New labs complete 2nd phase of company’s € 29 million...

November 30, 2023 | News

WuXi Biologics Achieves Breakthrough Productivity of ~6 g/L/day in Integrated Continuous Process at Pilot Scale

By leveraging WuXiUPTM, WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing from perfused cell culture...

November 23, 2023 | News

WuXi XDC Successfully Listed on the Main Board of Hong Kong Stock Exchange

WuXi XDC issued a total of 178,446,000 shares under the global offering at an offer price of HK$20.60 per share (being the high-end of the indica...

November 20, 2023 | News

Hilleman Laboratories Officially Opens US$20 Million Facility in Singapore to Bolster Resilience in Vaccine Manufacturing

Hilleman Laboratories, an organisation with a mission to develop affordable vaccines and biologics against infectious diseases with unmet medical need, off...

November 09, 2023 | News

Stay Connected